NCT02225223 2021-08-11
STARRT
Merit Medical Systems, Inc.
Phase NA Terminated
Clinical Trials
20 trialsNCT01964378 2021-07-15
CORAL
Tris Pharma, Inc.
Phase 3 Terminated
NCT00380874 2021-02-11
Prevention And Treatment Of Chemotherapy-Induced Peripheral Neuropathy In Subjects With Advanced Colorectal Cancer
Pfizer
Phase 4 Terminated
NCT01264887 2019-11-04
Tapentadol in Chronic Malignant Tumour Related Pain
Grünenthal GmbH
Phase 3 Terminated
NCT00505414 2019-11-01
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
Grünenthal GmbH
Phase 3 Terminated
NCT01696643 2018-11-15
Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901302 2018-11-15
Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01901341 2018-11-15
The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated
NCT00099177 2017-08-16
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Hoffmann-La Roche
Phase 3 Terminated
NCT00099203 2017-08-16
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Hoffmann-La Roche
Phase 3 Terminated
NCT01315886 2017-04-05
Conversion From Fast Acting Oral Opioids to Abstral®
Orexo AB
Phase 4 Terminated
NCT02081053 2017-01-20
EU-STAR
Merit Medical Systems, Inc.
Phase NA Terminated
NCT01014559 2015-09-28
OXN3505
Mundipharma SAS
Phase 3 Terminated
NCT01648699 2013-10-11
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
Janssen Pharmaceutica
Phase 4 Terminated
NCT00803283 2013-08-12
A Study to Compare Safety and Efficacy of Osmotic Release Oral Syytem (OROS) Hydromorphone Hydrochloride (HCl) With Morphine Sustain Release (SR) in Participants With Cancer Pain
Johnson & Johnson Taiwan Ltd
Phase 3 Terminated
NCT01439919 2013-03-21
ACT11705
Sanofi
Phase 2 Terminated
NCT00126789 2012-06-05
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
ZARS Pharma Inc.
Phase 3 Terminated
NCT00492388 2012-01-11
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
Hospira, now a wholly owned subsidiary of Pfizer
Phase 3 Terminated
NCT00101621 2006-02-09
Pilot Study to Evaluate the Safety and Analgesic Activity of M40403 Co-Administered With an Opioid Agent for Cancer Pain
MetaPhore Pharmaceuticals
Phase 2 Terminated